UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W | Y | Z
Number of items: 366.

A

Abola, EE; Bairoch, A; Barker, WC; Beck, S; Benson, DA; Berman, H; Cameron, G; ... CODATA Task Grp Biological Macromo, ; + view all (2000) Quality control in databanks for molecular biology. BIOESSAYS , 22 (11) 1024 - 1034.

Adeyemo, D; Imtiaz, F; Toffa, S; Lowdell, M; Winslet, M; (2000) Bax/Bcl-2 ratio is elevated by combines 5FU and antioxidant in colon cancer cells in vitro. GUT , 46 A54 - A54.

Adeyemo, D; Toffa, S; Lowdell, M; Winslet, M; (2000) Antioxidants augment 5FU upregulation of Bax expression in colon cancer cells in vitro. BRIT J CANCER , 83 58 - 58.

Ahmed, F; Watts, MJ; Ings, SJ; Flynn, M; Linch, DC; (2000) Poor viability of freshly apheresed PBSC harvests: Implications for overnight storage before cryopreservation or additional manipulative procedures. BLOOD , 96 (11) 380A - 380A.

Al Saffar, N; Burrows, MG; Revell, PA; (2000) Immunopathological reaction to orthopaedic biomaterial. In: Cracium, C and Ardelean, , (eds.) Current Problems in Cellular and Molecular Biology. (pp. 37-50). RISOPRINT: Cluj-Napoca.

Al Saffar, N; Revell, PA; (2000) Differential expression of transforming growth factor-alpha and macrophage colony-stimulating factor/colony-stimulating factor-1R (c-fms) by multinucleated giant cells involved in pathological bone resorption at the site of orthopaedic implants. Journal of Orthopaedic Research , 18 (5) pp. 800-807.

Al Saffar, N; Revell, PA; (2000) Heavy infiltrate of B-lymphocytic nodules/aggregates in the bone-implant interface in relation to orthopaedic protheses: Report of two cases. The Journal of Pathology , 192 (Suppl) 28A-28A.

Al Saffar, N; Revell, PA; (2000) Frustrated wound healing: the immunopathogenesis of bone resorption. In: Davies, JE, (ed.) Bone Engineering. (pp. 152-160). em squared incorporated: Toronto.

Alison, MR; Poulsom, R; Jeffrey, R; Dhillon, AP; Quaglia, A; Jacob, J; Novelli, M; ... Wright, NA; + view all (2000) Plasticity of human haemopoietic stem cells: Differentiation to hepatocytes after liver and bone marrow transplantation. J PATHOL , 192 2A - 2A.

Allcock, C; Allen, N; Anaf, G; Apler, A; Austin, MP; Bennett, C; Birleson, P; ... others, ; + view all (2000) Sections. Australasian Psychiatry , 8 (4) p. 409.

Allen, AJR; Gale, RE; Harrison, CN; Machin, SJ; Linch, DC; (2000) Lack of pathogenic mutations in the 5 ' UTR of the thrombopoietin gene in patients with non-familial essential thrombocythaemia. BLOOD , 96 (11) 742A - 742A.

Allford, SL; Harrison, P; Lawrie, AS; Cohen, H; Mackie, IJ; Machin, SJ; (2000) Recurrent thrombotic thrombocytopenic purpura: Association of durable remission with cyclosporin and recovery in vWF-cleaving protease activity. Presented at: UNSPECIFIED.

Allford, SL; Harrison, P; Lawrie, AS; Liesner, R; Mackie, IJ; Machin, SJ; (2000) von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology , 111 (4) pp. 1215-1222. 10.1046/j.1365-2141.2000.02503.x.

Allford, SL; Harrison, P; Lawrie, AS; Liesner, R; Mackie, IJ; Machin, SJ; (2000) von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. BRIT J HAEMATOL , 111 (4) 1215 - 1222.

Almeida, A; Mehta, A; (2000) Malaria and Anaemia. Postgraduate Doctor (Caribbean) , 16 (9) pp. 392-394.

Ancliff, PJ; Gale, RE; Liesner, R; Hann, IM; Linch, DC; (2000) Mutations in ELA2 encoding for neutrophil elastase are a frequent finding in sporadic but not familial severe congenital neutropenia. BLOOD , 96 (11) 445A - 445A.

Anthony, A; Pounder, RE; Dhillon, AP; Wakefield, AJ; Inflammatory Bowel Disease Study G, ; (2000) Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. ALIMENT PHARM THER , 14 (2) 241 - 245.

Anthony, A; Sim, R; Dhillon, AP; Pounder, RE; Wakefield, AJ; (2000) Granulomatous vasculitis in Crohn's disease: Associated with the extra-mural vasculature. GASTROENTEROLOGY , 118 (4) A340 - A340.

Anthony, A; Sim, R; Guillaume, JL; Strosberg, AD; Dhillon, AP; Pounder, RE; Wakefield, AJ; (2000) Beta(beta)(3)-adrenergic receptors in human pancreatic islet and duodenal somatostatin neuroendocrine cells. ALIMENT PHARM THERAP , 14 (5) 579 - 585.

Ardeshna, KM; Walker, SJ; Devereux, S; Linch, DC; Khwaja, A; (2000) The p38 stress activated protein kinase mediates the increased responsiveness of mature dendritic cells to macrophage inhibitory protein 3 beta (MIP3 beta) and secondary lymphoid chemokine (SLC). BLOOD , 96 (11) 33A - 33A.

Ardeshna, KM; Walker, SJ; Devereux, S; Linch, DC; Khwaja, A; (2000) The p38 stress activated protein kinase mediates the increased responsiveness of mature dendritic cells to macrophage inhibitory protein 3β (mip3β) and secondary lymphoid chemokine (slc). Blood , 96 (11 PART )

Arguello, JR; Madrigal, JA; (2000) DNA conformational analysis. In: Bidwell, J and Navarette, C, (eds.) Histocompatibility Testing. (pp. 247-266). Imperial College Press: UK.

Arkenau, HT; Hegglin, I; Lüthi, U; (2000) [Trichosporosis]. Schweiz Med Wochenschr , 130 (49) 1914-.

Arkenau, HT; Luthi, U; (2000) Amyloidomas. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT , 130 (35) p. 1244.

Arnold, J; Cohen, H; (2000) Heparin-induced skin necrosis. British journal of haematology , 111 992-.

Arostegui, JI; Gallardo, D; Rodriguez-Luaces, M; Querol, S; Madrigal, JA; Garcia-Lopez, J; Granena, A; (2000) Genomic typing of minor histocompatibility antigen HA-1 by reference strand mediated conformation analysis (RSCA). Tissue Antigens , 56 pp. 69-76.

Ashford, P; Gozzard, D; Jones, J; Revill, J; Wallis, J; Bruce, M; Chapman, J; ... British Committee for Standards in Haematology Blood Transfusion, F; + view all (2000) Guidelines for blood bank computing. Transfusion medicine , 10 pp. 307-314.

Aubert, G; Dodi, A; Koh, M; Grace, S; Potter, M; Prentice, G; Travers, P; (2000) Monitoring of cytomegalovirus antigen specific T cells in post bone marrow transplant patients. Human Immunology , 61 (Suppl)

Azzabi, AS; Calvert, AH; Verrill, M; Kelly, C; Lind, MJ; Newell, DR; Griffin, MJ; ... Boddy, AV; + view all (2000) Phase I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clinical Cancer Research , 6 539-.

B

Baddeley, H; Brodrik, PM; Taylor, NJ; Abdelatti, MO; Jordan, LC; Vasudevan, AS; Phillips, H; ... Hoskin, PJ; + view all (2000) Gas exchange parameters in radiotherapy patients during breathing of 2%, 3.5% and 5% carbogen gas mixtures. British Journal of Radiology , 73 (874) pp. 1100-1104.

Baker, RJ; Hart, SM; Mehta, AB; Wickremasinghe, RG; Prentice, HG; Hoffbrand, AV; Ross, DD; (2000) Expression of breast cancer resistance protein (BCRP) in malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and acute lymphoblastic leukemia (ALL). BLOOD , 96 (11) 824A - 824A.

Barlow, HC; Bowman, KJ; Curtin, NJ; Calvert, AH; Golding, BT; Huang, B; Loughlin, PJ; ... Griffin, RJ; + view all (2000) Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha(1)-acid glycoprotein (AGP). BIOORG MED CHEM LETT , 10 (6) 585 - 589.

Bates, AW; Norton, AJ; Baithun, SI; (2000) Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. J CLIN PATHOL , 53 (6) 458 - 461.

Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; ... UK Canc Cytogenetics Grp, ; + view all (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. ONCOGENE , 19 (34) 3902 - 3913.

Bentley, J; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Gibson, AE; ... Newell, DR; + view all (2000) Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research , 6 328-.

Bentzen, SM; Hoskin, P; Roos, D; Nielsen, OS; (2000) Fractionated radiotherapy for metastatic bone pain: Evidence- based medicine or ...? International Journal of Radiation Oncology Biology Physics , 46 (3) pp. 681-682.

Bentzen, SM; Saunders, MI; Dische, S; Parmar, MK; (2000) Updated data for chart in NSCLC: Further analyses. RADIOTHERAPY AND ONCOLOGY , 55 (1) pp. 86-87. 10.1016/S0167-8140(00)00160-2.

Berardi, R; Strauss, S; Blake, D; Whelan, JS; (2000) Is it safe to substitute oral for intravenous mesna? A case control study. In:

Berger, LA; Warwick, R; Mehta, A; (2000) Isolated candida infection of the pterygoid muscles in a patient with Gauchers disease. American Journal of Rentgenology , 176 1332-.

Beverley, PCL; Maini, MK; (2000) Differences in the regulation of CD4 and CD8 T-cell clones during immune responses. In: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. (pp. 401 - 406). ROYAL SOC LONDON

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RH; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer , 85 (4) pp. 571-577.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RHJ; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv :: carboxypeptidase G2 fusion protein. INT J CANCER , 85 (4) 571 - 577.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RHJ; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. International Journal of Cancer , 85 (4) pp. 571-577. 10.1002/(SICI)1097-0215(20000215)85:4<571::AID-IJC20>3.0.CO;2-1.

Bhatia, J; Sharma, SK; Pedley, BR; Boxer, G; Robson, L; Begent, RHJ; Chester, K; (2000) In vitro & in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: (pp. p. 71). CHURCHILL LIVINGSTONE

Bhatia, J; Sharma, SK; Pedley, BR; Boxer, G; Robson, L; Begent, RHJ; Chester, K; (2000) In vitro and in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: (pp. p. 170).

Boddy, AV; Griffin, MJ; Wright, JG; Sludden, JA; Thomas, HD; Fishwick, K; Plummer, R; ... Calvert, AH; + view all (2000) Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer , 83 203-.

Bodmer, JG; Bodmer, WF; Marsh, SGE; (2000) HLA Nomenclature: The Name of the Rose. In: Lecher, R and Warrens, A, (eds.) HLA and Disease. (pp. 147-161). Academic Press: London.

Boehm, MK; Corper, AL; Wan, T; Sohi, MK; Sutton, BJ; Thornton, JD; Keep, PA; ... Perkins, SJ; + view all (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J , 346 Pt pp. 519-528.

Bogunia-Kubik, K; Perez-Cruz, I; Fallen, PR; Madrigal, JA; Cohen, SBA; (2000) Cord blood lymphocytes have a low frequency of cytokine producing T cells due to a high threshold for activation. IMMUNOL LETT , 72 (3) pp. 145-146.

Brady, CS; Bartholomew, JS; Burt, DJ; Duggan-Keen, MF; Glenville, S; Telford, N; Little, AM; ... Stern, PL; + view all (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens , 55 (5) pp. 401-411.

Burcombe, RJ; Makris, A; Richman, PI; Daley, F; Noble, S; Wilson, GD; (2000) Persistence of c-erbB-2 overexpression after neoadjuvant chemotherapy for primary breast cancer. British Journal of Cancer , 83 36-.

Burcombe, RJ; Ostler, PJ; Ayoub, AW; Hoskin, PJ; (2000) The role of staging CT scans in the treatment of prostate cancer: A retrospective audit. Clinical Oncology , 12 (1) pp. 32-35.

Burk, K; (2000) Troublemaker: The Life and History of A.J.P. Taylor. [Book]. Yale University Press: London & New Haven.

Burk, K; (2000) War and Anglo-American Financial Relations in the Twentieth Century. In: Levanthal, F and Quinault, R, (eds.) Anglo-American Attitudes: From Revolution to Partnership. (pp. 243-260). Ashgate Press: Aldershot.

C

COULONVAL, K; VANDEPUT, F; STEIN, RC; KOZMA, SC; LAMY, F; DUMONT, JE; (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochemical Journal , 348 (2) pp. 351-358. 10.1042/bj3480351.

Calabrese, CR; Curtin, NJ; Canan-Koch, SS; Batey, MA; Thomas, HD; Kyle, S; Wang, LZ; ... Newell, DR; + view all (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clinical Cancer Research , 6 150-.

Calder, JDF; Buttery, L; Revell, P; Polak, JM; Pearse, M; (2000) Apoptosis - The underlying mechanism of cellular death in osteonecrosis of the femoral head? The Journal of Pathology , 190 (SS) A21-.

Calder, JDF; Buttery, L; Revell, P; Polak, JM; Pearse, M; (2000) Increased eNOS and iNOS expression in osteonecrosis of the femoral head. The Journal of Pathology , 190 (SS) A22-.

Calder, JDF; Pearse, M; Revell, P; (2000) Extension of osteonecrosis into the proximal femur of patients with osteonecrosis of the femoral head. The Journal of Pathology , 190 (SS) A22-.

Calvert, H; Sessa, C; Carmichael, J; Calvert, P; Zucchetti, M; Marsoni, S; Van den Bosch, S; ... Camboni, G; + view all (2000) An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex. ANN ONCOL , 11 132 - 132.

Calvert, P; Jayson, G; Atkinson, R; Ganesan, T; Cervantes-Ruiperez, A; Vasey, P; Adams, M; ... Cheverton, P; + view all (2000) Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane. Annals of Oncology , 11 372P-.

Calvert, PM; O'Neill, V; Azzabi, A; Hughes, A; Plummer, R; Twelves, C; Robinson, A; ... Calvert, AH; + view all (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. Clinical Cancer Research , 6 575-.

Caplin, ME; Hilson, AJ; Hochhauser, D; Burroughs, AK; Tibbals, J; Watkinson, AF; Dhillon, AP; (2000) High dose Indium-III Octreotide therapy for disseminated carcinoid tumour. Gastroenterology , 118 (4 Supp) AGA-.

Caplin, ME; Hilson, AJ; Hochhauser, D; Burroughs, AK; Tibbals, J; Watkinson, AF; Dhillon, AP; (2000) High dose indium-111 octreotide therapy for disseminated carcinoid tumour. GUT , 46 A74 - A74.

Caplin, ME; Hilson, AJ; Hochhauser, D; Burroughs, AK; Tibbals, J; Watkinson, AF; Dhillon, AP; (2000) High dose indium-III octreotide therapy for disseminated carcinoid tumor. Gastroenterology , 118 (4) 2751-.

Caplin, ME; Hilson, AJ; Hochhauser, D; Burroughs, AK; Tibbals, J; Watkinson, AF; Dhillon, AP; (2000) High dose indium-III octreotide therapy for disseminated carcinoid tumor. GASTROENTEROLOGY , 118 (4) A516 - A516.

Carmichael, J; Conron, M; Beynon, H; Crow, J; Warner, TT; (2000) Churg-Strauss syndrome presenting with visual loss. RHEUMATOLOGY , 39 (12) 1433 - 1434.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, A; Yarranton, GTAB; R, HJ; (2000) Improved tumour targetting of divalent Fab’ fragments modified with polyethylene glycol. Tumor Targeting , 4 pp. 235-244.

Chakraverty, R; McMillan,, AK; Chopra, R; Goldstone, AH; (2000) High dose therapy for the treatment of non-Hodgkin's lymphoma. In: Armitage, JO and Antman, KH, (eds.) High Dose Cancer Therapy. Williams and Wilkins

Chang, J; Powles, TJ; Allred, DC; Ashley, SE; Makris, A; Gregory, RK; Osborne, CK; (2000) Prediction of clinical outcome from primary tamosifen by expression of biologic markers in breast cancer patients. Clinical Cancer Research , 6 (2) pp. 616-621.

Chatterjee, R; Kottaridis, PD; Lees, WR; Ralph, DJ; Goldstone, AH; (2000) Cavernosal arterial insufficiency and erectile dysfunction in recipients of high-dose chemotherapy and total body irradiation for multiple myeloma. LANCET LTD

Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DI; Cooke, SP; Flynn, AA; ... Begent, RH; + view all (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol , 46 Sup S8-12.

Cirinna, M; Trotta, R; Salomoni, P; Kossev, P; Wasik, M; Perrotti, D; Calabretta, B; (2000) Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. BLOOD , 96 (12) 3915 - 3921.

Clingen, PH; Denholm, EE; De Silva, IU; Hockey, A; Hartley, JA; (2000) Response of human DNA repair defective cell lines to DNA interstrand agents. British Journal of Cancer , 83 138-.

Codish, S; Abu-Shakra, M; Ariad, S; Zirkin, HJ; Yermiyahu, T; Dupin, N; Boshoff, C; (2000) Manifestations of three HHV-8-related diseases in an HIV-negative patient: Immunoblastic variant multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma. AM J HEMATOL , 65 (4) 310 - 314.

Codrington, R; O'Connor, HE; Jalali, GR; Carrara, P; Papaioannou, M; Hart, SM; Hoffbrand, AV; ... Foroni, L; + view all (2000) Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value. BRITISH JOURNAL OF HAEMATOLOGY , 111 (4) pp. 1071-1079. 10.1046/j.1365-2141.2000.02464.x.

Cohen, H; Love, E; Williamson, L; Jones, H; (2000) Serious hazards of transfusion: a scheme for haemovigilance. Presented at: 28th world congress of the international society of haematology, Toronto.

Cohen, SB; Woolley, J; Bogunia-Kubik, K; Natarajan, P; Kotecha, R; Belaramani, L; Fallen, PR; ... Madrigal, JA; + view all (2000) Macrophage colony stimulating factor (M-CSF) within cord blood sera may be partially responsible for the reduced proliferation of cord blood T cells. European Cytokine Network , 11 (4) pp. 608-617.

Cohen, SBA; Gluckman, E; Rubinstein, P; Madrigal, JA; (2000) Cord Blood Characteristics: Role in Stem Cell Transplantation. Martin Dunitz: London.

Cohen, SBA; Morgan, CL; Perez-Cruz, I; Perandin, F; Martinez, B; Madrigal, JA; (2000) Cord blood serum does not increase lymphocyte responses in comparison to adult serum. HUM IMMUNOL , 61 pp. 111-114.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. British Journal of Cancer , 83 14-.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. British Journal of Cancer , 83 (Suppl) 14-.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. BRIT J CANCER , 83 11 - 11.

Cooooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. In: (Proceedings) British Journal of Cancer. (pp. p. 14).

Coulonval, K; Vandeput, F; Stein, RC; Kozma, SC; Lamy, F; Dumont, JE; (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J , 348 Pt pp. 351-358.

Cox, ST; Hossain, E; McWhinnie, A; Prokupek, B; Madrigal, JA; Little, AM; (2000) HLA-B*8202 identified in a Caucasoid potential bone marrow donor. Tissue Antigens , 56 (2) pp. 188-191.

Cox, ST; Hossain, E; McWhinnie, A; Prokupek, B; Madrigal, JA; Little, AM; (2000) HLA-B*8202 identified in a Caucasoid potential bone marrow donor. Tissue Antigens , 56 (2) pp. 188-191.

Cox, ST; Little, AM; Madrigal, JA; Marsh, SGE; (2000) Sequence of HLA-A*0209 confirmed. IMMUNOGENETICS , 51 (6) pp. 489-490. 10.1007/s002510050648.

Cox, ST; McWhinnie, A; Prokupek, B; Madrigal, JA; Little, AM; (2000) HLA-B*4413 identified in a UK Caucasoid potential bone marrow donor. Tissue Antigens , 55 (2) pp. 185-187.

Cox, ST; McWhinnie, A; Prokupek, B; Madrigal, JA; Little, AM; (2000) HLA-B*4413 identified in a UK Caucasoid potential bone marrow donor. Tissue Antigens , 55 (2) pp. 185-187.

Crow, JC; Rolfe, KJ; Levine, TS; Reid, W; MacLean, AB; Perrett, CW; (2000) Lichen sclerosus, squamous hyperplasia and differentiated VIN - a pathway to vulval malignancy. J PATHOL , 192 22A - 22A.

Cunningham, D; Mainwaring, PN; Gregory, W; Hoskin, P; Hancock, B; Smith, P; Hudson, GV; (2000) Mitoxantrone is superior to doxorubicin in a multi-agent weekly regimen for patients with high-grade lymphoma over the age of 60 years: Results of a BNLI randomised trial of PACEBO vs. British Journal of Cancer , 83 (Su 1-.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; ... Yu, XH; + view all (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clinical Cancer Research , 6 205-.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; ... Yu, XH; + view all (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. CLIN CANCER RES , 6 4507S - 4507S.

D

Dearling, JLJ; Flynn, AA; Pagoulatos, C; Wilson, GD; Woodcock, M; Denholm, E; Hartley, J; ... Pedley, RB; + view all (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. British Journal of Cancer , 83 (Suppl) 173-.

Dearling, JLJ; Flynn, AA; Watson, RJ; Boxer, GM; Sutcliffe-Goulden, J; Boden, R; Begent, RHJ; (2000) : Potential for use of [C-14]2DG as a predictor of [F-18]FDG tumour distribution for assessment of therapeutic efficacy. In: (pp. pp. 394-395).

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. British Journal of Cancer , 83 152-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. Clinical Cancer Research , 6 309-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. British Journal of Cancer , 83 152-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. Clinical Cancer Research , 6 309-.

Ding, GR; Yaguchi, H; Yoshida, M; Miyakoshi, J; (2000) Increase in X-ray-induced mutations by exposure to magnetic field (60 Hz, 5 mT) in NF-kappaB-inhibited cells. Biochem Biophys Res Commun , 276 (1) pp. 238-243. 10.1006/bbrc.2000.3455.

Dodi, IA; Morgan, CL; Madrigal, JA; (2000) The significance of HLA matching in cord blood stem cell transplantation. In: Cohen, SBA and Gluckman, E and Rubinstein, P and Madrigal, JA, (eds.) Cord Blood Transplantation. (pp. 205-238). Martin Dunitz Ltd: London.

Dodi, IA; Morgan, CL; Madrigal, JA; (2000) The significance of HLA matching in cord blood stem cell transplantation. In: Cohen, SBA and Gluckman, E and Rubinstein, P and Madrigal, JA, (eds.) Cord Blood Transplantation. (pp. 205-238). Martin Dunitz Ltd: London.

Duke, V; Kapoor, A; Gricks, C; Melo, J; Foroni, L; (2000) BCL10 deletions in haematological malignancies: a cloning artefact? BRITISH JOURNAL OF HAEMATOLOGY , 111 (4) pp. 1106-1108. 10.1046/j.1365-2141.2000.02447.x.

Dunlop, DJ; Connery, L; O, BM; Thatcher, N; Lee, SM; Hill, S; Thatcher, N; (2000) Phase II study of carboplatin and vinorelbine in small cell lung cancer. In: (Proceedings) 2000 ASCO Annual Meeting/36th Annual Meeting, New Orleans, LA.. (pp. 518a-). Proceedings of the American Society of Clinical Oncology

E

Eccles, DM; Evans, DG; Mackay, J; (2000) Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). Journal of Medical Genetics , 37 (3) pp. 203-209.

El Hamidi, A; Kocjan, G; Du, MQ; (2000) Cervical smear: A PCR-based clonality analysis. J PATHOL , 192 25A - 25A.

Ellis, PE; Fong, LFWT; Rolfe, KJ; Crow, JC; MacLean, AB; Perrett, CW; (2000) Vascular Endothelial Growth Factor (VEGF) and disease progression in Paget's disease of the vulva and the breast. J PATHOL , 192 23A - 23A.

Eren, E; Travers, PJ; (2000) The molecular structure of the major histocompatibility complex and its molecular interactions. In: Lechler, R and Warrens, A, (eds.) HLA in Health and Disease. Academic Press

Ezoe, S; Matsumura, I; Tanaka, H; Kawasaki, A; Machii, T; Enver, T; Kanakura, K; (2000) GATA-1 inhibits cytokine-dependent growth of hematopoietic cells through the inhibition of STAT3 and AP-1 activities. BLOOD , 96 (11) 680A-680A.

Ezoe, S; Matsumura, I; Tanaka, H; Kawasaki, A; Machii, T; Enver, T; Kanakura, Y; (2000) GATA-2 down-regulates c-myc and affects cytokine-dependent growth of hematopoietic cells. BLOOD , 96 (11) 285A-285A.

F

Fischer, G; Perez-Rodriguez, M; Arguello, JR; Cox, ST; McWhinnie, A; Travers, PJ; Madrigal, JA; (2000) Three novel MICB alleles. Tissue Antigens , 55 (2) pp. 166-170.

Flanagan, AM; Sarma, U; Steward, CG; Vellodi, A; Horton, MA; (2000) Study of the nonresorptive phenotype of osteoclast-like cells from patients with malignant osteopetrosis: A new approach to investigating pathogenesis. J BONE MINER RES , 15 (2) 352 - 360.

Flores, NA; Botchway, ANS; Turner, MA; Cohen, H; Sheridan, DJ; (2000) Products of the platelet release reaction accentuate the ischaemia-induced reduction in action potential duration (APD(95)) in the isolated perfused guinea-pig heart. In: J PHYSIOL-LONDON. (pp. 111P - 112P). CAMBRIDGE UNIV PRESS

Flores, NA; Botchway, ANS; Turner, MA; Cohen, H; Sheridan, DJ; (2000) Products of the platelet release reaction influence cardiac electrophysiology independently of platelet-platelet interactions. PLATELETS , 11 (7) 415 - 417.

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; Boden, B; (2000) A model based approach for the optimisation of radioimmunotherapy through antibody design and radionuclide selection. Cancer Biotherapy and Radiopharmaceuticals , 15 (4 2000)

Flynn, AA; Pedley, RB; Green, AJ; Boxer, GM; Dearling, J; Watson, R; Boden, B; (2000) Multiparameter analysis using 3D reconstructions of digital images showing the spatial and temporal distribution of factors influencing radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals , 15 (4 2000)

Foss, HD; Marafioti, T; Stein, H; (2000) The many faces of anaplastic large cell lymphoma. PATHOLOGE , 21 (2) pp. 124-136. 10.1007/s002920050380.

Francis, RJ; Sharma, SK; Sena, L; Springer, C; Green, AJ; Hope-Stone, LD; Martin, J; ... Begent, RHJ; + view all (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 83 (Suppl) 18-.

Francis, RJ; Sharma, SK; Sena, L; Springer, C; Green, AJ; Hope-Stone, LD; Martin, J; ... Begent, RHJ; + view all (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 83 43-.

G

Gardiner, C; Mackie, IJ; Machin, SJ; (2000) Evaluation of a new automated latex particle immunoassay for D-dimer: IL test D-dimer. Laboratory Hematology , 6 (3) pp. 147-150.

Gascoigne, NRJ; Alam, SM; Lin, CM; McGuire, MV; Marine, S; Niederberger, N; Redpath, S; ... Zal, T; + view all (2000) T cell receptor binding kinetics and special role of V alpha in T cell development and activation. Immunologic Research , 21 (2-3) pp. 225-231.

Gorodetsky, R; Lotan, C; Piggot, K; Pierce, L; Polyansky, I; Dische, S; Saunders, MI; ... Vexler, A; + view all (2000) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy (vol 45, pg 893, 1999). International Journal of Radiation Oncology Biology Physics , 47 (2) p. 545.

Grant, JW; Scott, IS; Stoeber, K; Happerfield, LC; Anderson, JR; Williams, GH; (2000) Comparison of expression of minichromosome maintenance protein 2 and MIB-1 in primary CNS tumours. In: (Proceedings) 181st Meeting of the Pathological Society of Great Britain and Ireland. (pp. A9-A9). Wiley: Hoboken, NJ.

Greene, JN; Linch, DC; Miller, CB; (2000) Current treatments for infection in neutropenic patients with hematologic malignancy. Oncology (Williston Park) , 14 (8 Suppl ) pp. 31-34.

Gribble, S; Andrews, K; Williams, D; Tillett, A; Bloxham, D; Proffit, J; Hackbarth, M; ... Nacheva, E; + view all (2000) Fluorescence in situ hybridization detection of two telomeres on the short arm of a derived chromosome 16 in an infant with thrombocytopenia. Cancer Genet Cytogenet , 120 (2) pp. 99-104.

Gribble, S; Bench, A; Huntly, B; Green, AR; Nacheva, EP; (2000) Molecular cytogenetics of polycythemia vera; Lack of occult rearrangements detectable by FISH mapping, CGH, and colour karyotyping. BLOOD , 96 (11) 742A - 742A.

Gribble, S; Philips, M; Andrews, K; Roberts, I; Morrison, L; Grace, CD; Green, AR; (2000) Chromosome segment 8q23-qter identified as a common region of overrepresentation in CML blast crisis; A study of 10 CML derived cell lines using CGH, colour karyotyping, chromosome band specific painting and FISH mapping. BLOOD , 96 (11) 740A - 740A.

Gribble, SM; Roberts, I; Grace, C; Andrews, KM; Green, AR; Nacheva, EP; (2000) Cytogenetics of the chronic myeloid leukemia-derived cell line K562: Karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization. In: CANCER GENET CYTOGEN. (pp. 1 - 8). ELSEVIER SCIENCE INC

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; ... Lawrie, A; + view all (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society , 219 296-MEDI.

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; ... Lawrie, A; + view all (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. ABSTR PAP AM CHEM S , 219 U55 - U55.

Groot De, NG; Otting, N; Watkins, DI; Doxiadis, GM; Arguello, R; Madrigal, JA; Bontrop, RE; (2000) MHC class I diversity in a West-African chimpanzee population: implications for HIV research. Immunogenetics , 51 pp. 398-409.

Gudi, M; Hasserjian, R; Gomez, K; Abboudi, Z; Kaczmarski, R; Szydlo, R; Lampert, I; (2000) Prognostic factors in high grade non-hodgkin's lymphomas in the elderly. Blood , 96 (11 PART )

Guo, AL; Salomoni, P; Luo, JY; Shih, A; Zhong, S; Gu, W; Pandolfi, PP; (2000) Role of PML in p53-dependent apoptosis. BLOOD , 96 (11) 822A - 822A.

H

Hackshaw, AK; Law, MR; Wald, NJ; (2000) Passive smoking and lung cancer: increased risk is not disputed. British Medical Journal , 321 pp. 1221-1222.

Hampel, C; Tolner, B; Webley, SD; Lam, E; Hartley, JA; Hochhauser, D; (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. British Journal of Cancer , 83 (Suppl) 65-.

Hampel, C; Tolner, B; Webley, SD; Lam, E; Hartley, JA; Hochhauser, D; (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. BRIT J CANCER , 83 23 - 23.

Harland, PC; Harland, SJ; (2000) John Charles Harland - Obituaries. BMJ (Clinical Research Ed.) , 320 (7242) p. 1149.

Harland, SJ; (2000) Conundrum of the hereditary component of testicular cancer. LANCET , 356 (9240) 1455 - 1456.

Hart, SM; Ganeshaguru, K; Mehta, A; (2000) Multi-drug resistance in haematological malignancies. CME Bulletin Haematology , 3 (1) pp. 6-8.

Hartley, JA; Brooles, PJ; Mc Hugh, PJ; Clingen, PH; Gregson, SJ; Howard, PW; and Thurston, DE; (2000) SJG-136 (NSC-D694501)-A novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity. PROC AM ASSOC CANCER RES , 41 2703-.

Hartley, JA; Hazrati, A; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; Walker, LF; (2000) A Synthetic Azinomycin Analogue with Demonstrated DNA Cross-Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent The authors gratefully acknowledge the financial support provided by the CRC and the EPSRC. We are indebted to the EPSRC National Mass Spectrometry Centre for performing mass spectral measurements, and the EPSRC Chemical Database Service at Daresbury.1. Angew Chem Int Ed Engl , 39 (19) pp. 3467-3470.

Helmberg, W; Hegland, J; Hurley, CK; Maiers, M; Marsh, SGE; Muller, C; Rozemuller, EH; (2000) Going back to the roots: effective utilisation of HLA typing information for bone marrow registries requires full knowledge of the DNA sequences of the oligonucleotide reagents used in the testing. TISSUE ANTIGENS , 56 (1) pp. 99-102. 10.1034/j.1399-0039.2000.560115.x.

Heyworth, CM; May, GE; Dexter, M; Gale, KB; Enver, T; (2000) Lineage programming and re-programming by transcription factor GATA-1. BLOOD , 96 (11) 454A-454A.

Hing, KA; Gibson, IR; Revell, PA; Best, SM; Bonfield, W; (2000) Influence of phase purity on the in vivo response to hydroxyapatite. Bioceramics , 192-1 pp. 373-376.

Horwich, A; Oliver, RTD; Wilkinson, PM; Mead, GM; Harland, SJ; Cullen, MH; Roberts, JT; ... MRC Testicular Tumour Working Par, ; + view all (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. BRIT J CANCER , 83 (12) 1623 - 1629. 10.1054/bjoc.2000.1498.

Hoskin, PJ; (2000) Palliative radiotherapy for disseminated disease. In: Greco, C and Zelefsky, MJ, (eds.) Radiotherapy of prostate cancer. (pp. 463-477). Harwood Academic Publishers: Amsterdam.

Hoskin, PJ; (2000) Bone metastases - radiotherapy. In: Rubens, RD and Mundy, GR and Martin, D, (eds.) Cancer and the skeleton. (pp. 159-170). : London.

Hoskin, PJ; Phillips, H; Jackson, S; Wims, P; Verma, N; Saunders, MI; (2000) Carbogen and nicotinamide with radical radiotherapy for bladder cancer: Updated Phase II results and launch of the BCON Phase III randomised trial. British Journal of Cancer , 83 84-.

Hoskin, PJ; Stratford, MRL; Folkes, LK; Regan, J; Yarnold, JR; (2000) Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. The Lancet , 355 (9213) pp. 1428-1429.

Hoskin, PJ; Vidler, K; (2000) Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. British Journal of Radiology , 73 (872) pp. 864-866.

J

Jackson, A; Carrara, P; Duke, V; Sinclair, P; Papaioannou, M; Harrison, CJ; Foroni, L; (2000) Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Research , 60 (11) pp. 2775-2779.

Jamieson, NF; Novelli, M; Thorpe, SM; Mosse, A; Bown, SG; Lovat, LB; (2000) Photodynamic therapy using ALA for high grade dysplasia in Barrett's oesophagus. In: (pp. 722-).

Jankowska, PJ; Babb, P; Quinn, M; Whelan, JS; (2000) A population based study of the incidence and mortality for osteosarcoma in England and Wales. In:

Joiner, M; Short, S; Mayes, C; Lambin, P; Marples, B; Shah, N; Saunders, MI; (2000) Low dose hypersensitivity and induced radioresistance: Possibilities for therapy and implications for radioprotection. International Journal of Radiation Oncology Biology Physics , 46 (3) p. 692.

Jones, DT; Wickremasinghe, RG; Mehta, AB; Prentice, HG; Ganeshaguru, K; (2000) Enchancement of the TNF-related apoptis-inducing ligand (TRAIL) mediated apoptosis of AML cells by cytotoxic agents. BLOOD , 96 (Abstr) 79a-.

Jones, DT; Wickremasinghe, RG; Mehta, AB; Prentice, HG; Hoffbrand, AV; Ganeshaguru, K; (2000) Activation of caspase 8 in the absence of FAS ligation in the killing of B-CLL cells by cytotoxic drugs and radiation. British Journal of Haematology , 108 (Abstr) 72-.

Jones, DW; Mackie, IJ; Gallimore, MJ; Winter, M; (2000) Are antibodies to coagulation factor XII a risk factor for recurrent fetal loss? BLOOD , 96 (11) 269A - 269A.

K

Kenneally, A; Liang, B; Barber, LD; (2000) The peptide-binding motif of HLA-B*3505. Immunogenetics , 51 (10) pp. 866-868.

Keshtgar, M; Kocjan, G; Saunders, C; Davidson, T; Baum, M; Ell, PJ; Taylor, I; (2000) Imprint cytology and the sentinel node in breast carcinoma. In: (pp. 680-).

Keshtgar, MRS; Kocjan, G; Davidson, T; Ralphs, D; Taylor, I; Ell, PJ; (2000) Touch imprint cytology and the sentinel node in breast carcinoma. In: (Proceedings) Sentinel Node 2000.

Khakoo, SI; Ling, R; Scott, I; Dodi, AI; Harrison, TJ; Dusheiko, GM; Madrigal, JA; (2000) Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. GUT , 47 (1) 137 - 143.

Khakoo, SI; Ling, R; Scott, I; Dodi, AI; Harrison, TJ; Dusheiko, GM; Madrigal, JA; (2000) Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. Gut , 47 (1) pp. 137-143.

Kitchener, H; Ledermann, J; Miles, A; (2000) Key Advances in the Management of Ovarian Cancer. [Book]. UK Key Advances in Clinical Practice Series. Aesculapius Medical Press: London.

Koh, MBC; Prentice, HG; Corbo, M; Cotter, FE; Morgan, M; Ravell, P; Lowdell, MW; (2000) Alloantigen-specific T cell depletion: From the bench to the bedside via a murine model. Hematology and Cell Therapy , 42 (2-3) pp. 187-190.

Kottaridis, PD; Gale, RE; Frew, ME; Harrison, G; Langabeer, SE; Belton, AA; Walker, H; ... Linch, DC; + view all (2000) The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. BLOOD , 96 (11) 825A - 825A.

L

Langabeer, SE; Gale, RE; Walker, H; Linch, DC; (2000) Reported cryptic rearrangements of CBF beta-MYH11 in acute myeloid leukaemia are not due to false priming of contaminating DNA. LEUKEMIA , 14 (5) 944 - 945.

Law, MR; Hackshaw, AK; Wald, NJ; (2000) Mammography screening for breast cancer. Lancet , 355 pp. 749-750.

Lawrie, AS; Mackie, IJ; Purdy, G; Machin, SJ; (2000) Effect of instruments on lupus anticoagulant testing - Rebuttal. THROMB HAEMOSTASIS , 83 (2) 346 - 348.

Lea, NC; Orr, SJ; Williams, GH; Stoeber, K; Thomas, NSB; (2000) Inhibition by p16INK4A of induction and DNA-binding of the DNA replication factors Mcm2, Mcm3 and Cdc6 in human primary T-lymphocytes only occurs early during the G0/G1 transition. In: (Proceedings) American Society of Hematology 42nd Annual Meeting. (pp. 289A-289A). American Society of Hematology: Washington, US.

Ledermann, JA; (2000) High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. INT J GYNECOL CANCER , 10 53 - 56.

Ledermann, JA; Collins, S; (2000) Clinical trials in ovarian cancer. A selection of current and recently closed randomised studies. In: Kitchener, H and Ledermann, J and Miles, A, (eds.) Key Advances in the Management of Ovarian Cancer. Aesculapius Medical Press: London.

Ledermann, JA; Herd, R; (2000) High dose chemotherapy for ovarian cancer. In: Lorigan, P and Vandenberghe, E, (eds.) An Introduction to High-Dose Chemotherapy. Harwood Academic

Leonard, P; Ledermann, J; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5- fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer. Annals of Oncology , 11 191P-.

Leonard, P; Ledermann, J; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer. ANN ONCOL , 11 44 - 45.

Leonard, P; Ledermann, JA; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer. British Journal of Cancer , 83 44-.

Leonard, P; Ledermann, JA; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer. BRIT J CANCER , 83 19 - 19.

Linch, DC; Gosden, RG; Tulandi, T; Tan, S-L; Hancock, SL; (2000) Hodgkin's Lymphoma: Choice of Therapy and Late Complications. Hematology Am Soc Hematol Educ Program pp. 205-221. Gold open access

Lo, SK; Tolner, B; Rogers, G; Schapira, AHV; Hartley, JA; Hochhauser, D; (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. British Journal of Cancer , 83 56-.

Lopez-Matas, M; Rodriguez-Justo, M; Morilla, R; Catovsky, D; Matutes, E; (2000) Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica , 85 (11) pp. 1140-1145.

Lovat, LB; Pickard, D; Novelli, M; Ripley, PM; Francis, H; Bigio, IJ; Bown, SG; (2000) A novel optical biopsy technique using elastic scattering spectroscopy for dysplasia and cancer in Barrett's oesophagus. In: (pp. TH1-).

Lovat, LB; Pickard, D; Novelli, M; Ripley, PM; Francis, H; Bigio, IJ; Bown, SG; (2000) A novel optical biopsy technique using elastic scattering spectroscopy for dysplasia and cancer in Barrett's oesophagus. In: (pp. 4919-).

Love, EM; Cohen, H; Williamson, LM; Hilary, J; (2000) Haemovigilance in the UK: What have the first three years of the serious hazards of transfusion scheme (SHOT) achieved? TRANSFUSION , 40 (10) 44S - 45S.

Love, EM; Williamson, L; Cohen, H; Jones, H; (2000) The 1998/1999 annual SHOT report (on behalf of the serious hazards of transfusion steering group).

Lowdell, MW; (2000) Autologous leukaemia-reactive cd8+ nk cells are required for long-term survival after treatment for acute leukaemia. Blood , 96 (11 PART )

Lowdell, MW; Koh, MBC; (2000) Immunotherapy of AML: future directions. J CLIN PATHOL , 53 (1) 49 - 54.

Lydyard, PM; Lakhani, SR; Dogan, A; Holton, JM; Patterson, KG; Bolodeoku, J; Playfair, JHL; (2000) Pathology Integrated: An A-Z of Disease and Its Pathogenesis. [Book]. Arnold: London.

M

MacLean, AB; Reid, WMN; Rolfe, KJ; Gammell, SJ; Pugh, HEJ; Gatter, KC; Fong, ACWT; ... Perrett, CW; + view all (2000) Role of angiogenesis in benign, premalignant and malignant vulvar lesions. JOURNAL OF REPRODUCTIVE MEDICINE , 45 (8) 609 - 612.

Macdonald, C; Walker, S; Watts, M; Ings, S; Linch, DC; Devereux, S; (2000) Effect of changes in expression of the amphotropic retroviral receptor PiT-2 on transduction efficiency and viral titer: Implications for gene therapy. HUM GENE THER , 11 (4) 587 - 595.

Mackay, J; (2000) Genetic testing in breast cancer patients: options for gene carriers and high risk women. In: Dixon, JM, (ed.) Breast Cancer: Diagnosis and Management. (pp. 107-112).

Madrigal, JA; Shaw, BE; Brookes, P; Potter, M; Prentice, HG; Goldman, JM; Little, AM; ... Pay, AL; + view all (2000) The genetic factors which affect the outcome of unrelated bone marrow transplantation. BLOOD , 96 (11) 1792-.

Madrigal, JA; Shaw, BE; Brookes, P; Potter, M; Prentice, HG; Goldman, JM; Little, AM; ... Pay, AL; + view all (2000) The genetic factors which affect the outcome of unrelated bone marrow transplantation. Blood , 96 (11) 1792-.

Madrigal, JA; Shaw, BE; Brookes, P; Potter, M; Prentice, HG; Goldman, JM; Little, AM; ... Pay, AL; + view all (2000) The genetic factors which affect the outcome of unrelated bone marrow transplantation. BLOOD , 96 (11) 417A - 417A.

Mangion, J; Edkins, S; Goss, AN; Stratton, MR; Flanagan, AM; (2000) Familial craniofacial fibrous dysplasia: absence of linkage to GNAS1 and the gene for cherubism. J Med Genet , 37 (11) E37-.

Marafioti, T; Roncador, G; Gatter, KC; Mason, DY; (2000) B cell associated transcription factors in normal and neoplastic lymphoid tissue: A new category of markers that can identify both cell lineage and differentiation stage. Presented at: The 7th Workshop and Conference on Human Leucocyte Differentiation Antigens (HLDA7): Abstracts..

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update April/May 2000. Hum Immunol , 61 (8) pp. 841-842.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update April/May 2000. WHO Nomenclature Committee for Factors of HLA System. Tissue Antigens , 56 (3) pp. 286-288.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update December 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 55 (4) pp. 381-382.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update February 2000. WHO Nomenclature Committee for Factors of the HLA System. Hum Immunol , 61 (6) 630-.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update February 2000. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 55 (6) pp. 571-572.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update January 2000. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 55 (5) pp. 475-476.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update June 2000. WHO Nomenclature Committee for Factors of the HLA system. Hum Immunol , 61 (9) 950-.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update June 2000. WHO Nomenclature Committee for factor of HLA System. Tissue Antigens , 56 (3) pp. 289-290.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update March 2000. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 56 (1) pp. 103-104.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update October/November 1999. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 55 (2) pp. 191-194.

Marsh, SG; (2000) Nomenclature for factors of the HLA system, update October/November 1999. WHO Nomenclature Committee for factors of the HLA system. Hum Immunol , 61 (3) pp. 354-356.

Marsh, SG; WHO Nomenclature Committee for Factors of the HLA System, ; (2000) Nomenclature for factors of the HLA system, update October 2000. Hum Immunol , 61 (12) pp. 1404-1405.

Marsh, SG; WHO Nomenclature Committee for Factors of the HLA System, ; (2000) Nomenclature for factors of the HLA system, update September 2000. Hum Immunol , 61 (12) 1403-.

Marsh, SG; WHO Nomenclature Committee for Factors of the HLA System, ; (2000) Nomenclature for factors of the HLA system, update September 2000. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens , 56 (6) pp. 565-566.

Marsh, SGE; (2000) Nomenclature for factors of HLA system, update August 2000. HUMAN IMMUNOLOGY , 61 (10) pp. 1055-1056. 10.1016/S0198-8859(00)00204-4.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update April/May 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (4) pp. 251-252. 10.1046/j.1365-2370.2000.00229.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update December 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (2) p. 109. 10.1046/j.1365-2370.2000.00207.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update December 1999. HUMAN IMMUNOLOGY , 61 (4) pp. 425-426. 10.1016/S0198-8859(00)00102-6.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update February 2000. HUMAN IMMUNOLOGY , 61 (6) p. 630. 10.1016/S0198-8859(00)00134-8.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update February 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (3) p. 161. 10.1046/j.1365-2370.2000.00219.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update January 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (3) pp. 159-160. 10.1046/j.1365-2370.2000.00210.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update January 2000. HUMAN IMMUNOLOGY , 61 (5) pp. 528-529. 10.1016/S0198-8859(00)00116-6.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update July 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (5-6) pp. 433-434.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update July 2000. HUMAN IMMUNOLOGY , 61 (10) pp. 1053-1054. 10.1016/S0198-8859(00)00205-6.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update June 2000. HUMAN IMMUNOLOGY , 61 (9) p. 950. 10.1016/S0198-8859(00)00169-5.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update June 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (5-6) p. 431.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update March 2000. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (3) p. 163. 10.1046/j.1365-2370.2000.00224.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update October/November 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (2) pp. 105-107. 10.1046/j.1365-2370.2000.00208.x.

Marsh, SGE; (2000) Nomenclature for factors of the HLA system, update September 1999. EUROPEAN JOURNAL OF IMMUNOGENETICS , 27 (1) p. 55. 10.1046/j.1365-2370.2000.00201.x.

Marsh, SGE; Parham, P; Barber, L; (2000) The HLA Factsbook. [Book]. Academic Press

Maughan, T; James, R; Kerr, D; Ledermann, J; McArdle, C; Seymour, M; Johnston, C; (2000) Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. Annals of Oncology , 11 (Suppl) 185O-.

Mayer, A; Flynn, AA; Tsiompanou, E; Pedley, RB; Dearling, J; Boden, R; Begent, RHJ; (2000) Radioimmunotherapy is more effective in small tumours due to higher dose and dose rate. British Journal of Cancer , 83 16-.

Mayer, A; Flynn, AA; Tsiompanou, E; Pedley, RB; Dearling, J; Boden, R; Begent, RHJ; (2000) Radioimmunotherapy is more effective in small tumours due to higher dose and dose rate. In: BRIT J CANCER. (pp. 32 - 32). CHURCHILL LIVINGSTONE

Mayer, A; Shaw, J; 'Ath, SD; Price, P; Blesing, C; Corrie, P; (2000) A phase II study of gemcitabine and flutamide in advanced pancreatic cancer. BRITISH JOURNAL OF CANCER , 83 p. 18.

Mayer, A; Shaw, J; D'Ath, S; Price, P; Blesing, C; Corrie, P; (2000) Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer. ANNALS OF ONCOLOGY , 11 p. 68.

McGreavey, L; Fallen, PR; Ethel, M; Potter, M; Prentice, HG; Travers, PJ; Madrigal, JA; (2000) Analysis of reconstitution the T-cell compartment in patients undergoing stem cell transplantation. Human Immunology , 61 (Suppl) 497A-.

McGreavey, L; se, F; en, P; Ethel, M; Potter, M; Prentice, HG; nt, T; ... Madrigal, JA; + view all (2000) Analysis of reconstitution the T-cell compartment in patients undergoing stem cell transplantation. HUM IMMUNOL , 61 (Suppl) 497A-.

McHugh, PJ; Hartley, JA; (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. British Journal of Cancer , 83 139-.

McHugh, PJ; Hartley, JA; CRC Drug DNA Interactions Res Grp, ; (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. BRIT J CANCER , 83 63 - 63.

McNeish, IA; Kanfer, EJ; Haynes, R; Agarwal, R; Harland, SJ; Newlands, ES; Seckl, MJ; (2000) Paclitaxel-containing high dose chemotherapy for relapsed or refractory germ cell tumours. British Journal of Cancer , 83 86-.

Mehta, A; Mason, PJ; Vulliamy, TJ; (2000) Glucose-6-phosphate dehydrogenase deficiency. Best Practice and Research Clinical Haematology , 13 (1) pp. 21-38. 10.1053/beha.1999.0055.

Mehta, AB; Hoffbrand, AV; (2000) Haematology at a Glance. [Book]. Blackwell Science: Oxford.

Mestiri, S; Monastiri, K; Ben Ahmed, S; Bouaouina, N; Presneau, N; Bignon, YJ; Khairi, H; (2000) [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women]. Arch Inst Pasteur Tunis , 77 (1-4) pp. 11-15.

Middleton, MR; Lee, SM; Aranc, ; A, ; Wood, M; Thatcher, N; Margison, GP; (2000) 06-methyguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. International Journal of Cancer , 88 (3) pp. 469-473.

Middleton, MR; Ranson, M; Lee, SM; Bridgewater, J; McElhinney, RS; McMurry, TBH; Thatcher, N; ... Margison, GP; + view all (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. In: (Proceedings) 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam.. (pp. 4574S-). Clinical Cancer Research

Miyakoshi, J; Mori, Y; Yaguchi, H; Ding, G; Fujimori, A; (2000) Suppression of heat-induced HSP-70 by simultaneous exposure to 50 mT magnetic field. Life Sci , 66 (13) pp. 1187-1196.

Miyakoshi, J; Yoshida, M; Yaguchi, H; Ding, GR; (2000) Exposure to extremely low frequency magnetic fields suppresses x-ray-induced transformation in mouse C3H10T1/2 cells. Biochem Biophys Res Commun , 271 (2) pp. 323-327. 10.1006/bbrc.2000.2635.

Mungall, AJ; Beck, S; Cann, HM; Dunham, I; Trowsdale, J; Ziegler, A; (2000) Report of the Fourth International Chromosome 6 Workshop 1999. CYTOGENET CELL GENET , 88 (3-4) 174 - 182.

N

Nacheva, EP; Gribble, S; Andrews, K; Wienberg, J; Grace, CD; (2000) Screening for specific chromosome involvement in hematological malignancies using a set of seven chromosome painting probes - An alternative approach for chromosome analysis using standard FISH instrumentation. In: CANCER GENET CYTOGEN. (pp. 65 - 72). ELSEVIER SCIENCE INC

Napier, MP; Ledermann, JA; (2000) Novel chemotherapeutic agents in colorectal cancer. EUR J SURG ONCOL , 26 (6) 605 - 610. 10.1053/ejso.2000.0955.

Napier, MP; Ledermann, JA; (2000) Risk analysis in surgical oncology - Part I: Concepts and tools. European Journal of Surgical Oncology , 26 (6) pp. 599-604. 10.1053/ejso.2000.0954.

Napier, MP; Ledermann, JA; (2000) The management of advanced colorectal cancer. CME Bulletin Oncology , 2 (2) pp. 31-36.

Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; ... Begent, RHJ; + view all (2000) Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. CLIN CANCER RES , 6 (3) 765 - 772.

Nathwani, AC; Hanawa, H; Vandergriff, J; Kelly, P; Vanin, EF; Nienhuis, AW; (2000) Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Therapy , 7 (3) pp. 183-195.

Nitu-Whalley, IC; Lee, CA; Dhillon, AP; Mistry, PK; (2000) Management of liver failure in a hemophilic patient co-infected with human immunodeficiency and hepatitisC viruses. Review Series Hepatitis , 1 pp. 18-19.

Nitu-Whalley, IC; Lee, CA; Griffioen, A; Jenkins, PV; Pasi, KJ; (2000) Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. BRIT J HAEMATOL , 108 (2) 259 - 264.

Noble, KE; Harkness, D; Yong, KL; (2000) Interleukin 10 regulates cellular responses in monocyte/endothelial cell co-cultures. BRIT J HAEMATOL , 108 (3) 497 - 504.

O

O'Neil, E; Wickremasinghe, RG; Jackson, T; Grant Prentice, H; Lowdell, MW; (2000) CDSαon human natural killer cells may act as a costimulatory molecule. Blood , 96 (11 PART )

O'Neil, E; Wickremasinghe, RG; Jackson, T; Prentice, HG; Lowdell, MW; (2000) CD8 alpha on human natural killer cells may act as a costimulatory molecule. In: BLOOD. (pp. 43B - 43B). AMER SOC HEMATOLOGY

Oksenhendler, E; Meignin, V; Dupin, N; Boshoff, C; Isaacson, PG; Clauvel, JP; (2000) High incidence of non-Hogkin's lymphoma (NHL) in HIV/HHV8 associated Castleman's disease (CD). JAIDS: Journal of Acquired Immune Deficiency Syndromes , 23 (3) 38-.

Oliveros, JC; Blaschke, C; Herrero, J; Dopazo, J; Valencia, A; (2000) Expression profiles and biological function. In: (pp. pp. 106-117).

Orchard, KH; Cooper, MS; Wijdenes, J; Borchardt, P; Quadri, SM; Buscombe, JR; Hilson, AJ; ... Prentice, HG; + view all (2000) Pre-clinical evaluation of candidate antibodies for targeted radiotherapy for patients with multiple myeloma. Journal of Nuclear Medicine , 41 (5) 463-.

Orchard, KH; Cooper, MS; Wijdenes, J; Borchardt, P; Quadri, SM; Buscombe, JR; Hilson, AJ; ... Prentice, HG; + view all (2000) Pre-clinical evaluation of candidate antibodies for targeted radiotherapy for patients with multiple myeloma. J NUCL MED , 41 (5) 117P - 118P.

Orleans-Lindsay, JK; Prentice, HG; Lowdell, MW; (2000) Acute myleoid leukemia cells induce T cell but not NK cell unresponsiveness - Implications for the adoptive immunotherapy of leukemia. BLOOD , 96 (11) 116A - 116A.

Osborne, M; Glynne-Jones, A; Makris, A; (2000) Chemoradiation followed by immediate boost in squamous cell carcinoma of the anus. British Journal of Cancer , 83 71-.

P

Pang, KF; Ganeshaguru, K; Hart, SM; Wickremasinghe, RG; Prentice, HG; Hoffbrand, AV; Mehta, AB; (2000) Gene expression of multidrug resistant protein (MRP) homologues in B-CLL and AML cells. British Journal of Haematology , 108 71-.

Paterson, PJ; Marshall, SR; Shaw, B; Kendra, JR; Ethel, M; Kibbler, CC; Prentice, HG; (2000) Fatal invasive cerebral Absidia corymbifera infection following bone marrow transplantation. Bone Marrow Transplantation , 26 (6) pp. 701-703.

Patterson, LH; Paniwynk, Z; Pohrs, K; Teesdale-Spittle, PH; Hartley, JA; Plumb, J; (2000) A novel alkylating anthraquinone that is effective against resistant ovarian cancer cells. Proceedings of the American Association for Cancer Research , 41 2701-.

Pavlidis, N; Aamdal, S; Awada, A; Calvert, H; Fumoleau, P; Sorio, R; Punt, C; ... Hanauske, AR; + view all (2000) Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). CANCER CHEMOTH PHARM , 46 (2) 167 - 171.

Pearson, TC; Messinezy, M; Westwood, N; Green, AR; Bench, AJ; Green, AR; Huntly, BJP; ... Finazzi, G; + view all (2000) A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. Hematology Am Soc Hematol Educ Program pp. 51-68. Gold open access

Pedley, RB; Sharma, SK; Boxer, G; Flynn, AA; Boden, R; Watson, R; Dearling, J; ... Begent, RHJ; + view all (2000) Tumour eradication by combined antibody-directed and antivascular therapy. British Journal of Cancer , 83 19-.

Pedley, RB; Sharma, SK; Boxer, G; Flynn, AA; Boden, R; Watson, R; Dearling, J; ... Begent, RHJ; + view all (2000) Tumour eradication by combined antibody-directed and antivascular therapy. BRIT J CANCER , 83 13 - 13.

Pedley, RB; Sharma, SK; Boxer, GM; Flynn, AA; Boden, R; Watson, R; Dearling, J; ... R, HJ; + view all (2000) Tumour eradication by combined antibody-directed and antivascular therapy. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 13-).

Pedley, RB; Sharma, SK; Hill, SA; Boden, R; Boxer, GM; Flynn, AA; Springer, CJAB; (2000) Tumour ablation by combined antibody-directed and antivascular therapies. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 79-).

Perez-Cruz, I; Fallen, P; Madrigal, JA; Cohen, SBA; (2000) Naive T cells from cord blood have the capacity to make Types 1 and 2 cytokines. IMMUNOL LETT , 75 (1) pp. 85-88.

Pettet, E; Phillips, H; Jackson, S; Saunders, MI; (2000) The time span between symptom onset and the start of radiotherapy in the treatment of head and neck tumours - A retrospective review. British Journal of Cancer , 83 78-.

Pezzella, F; Munson, PJ; Miller, KD; Goldstone, AH; Gatter, KC; (2000) The diagnosis of low-grade peripheral B-cell neoplasms in bone marrow trephines. BRITISH JOURNAL OF HAEMATOLOGY , 108 (2) pp. 369-376.

Pharoah, P; Mackay, J; (2000) Medical genetics and breast cancer: current thinking on the utility of genetic screening in the determination of clinical risk. In: Mansel, R and Smith, IE and Kunkler, I and Miles, A, (eds.) The Effective Management of Breast Cancer. (pp. 13-28). Aesculapius: London.

Pickard, DCO; Lovat, L; Novelli, M; Ripley, P; Kelly, C; Bigio, IJ; Bown, SG; (2000) Diagnosis of dysplasia in Barrett's oesophagus with in-situ elastic-scattering spectroscopy. OPTICAL BIOPSY AND TISSUE OPTICS , 1 (32) 122 - 130.

Pigott, KH; Dische, S; Vojnovic, B; Saunders, MI; (2000) Sweat gland function as a measure of radiation change. Radiotherapy And Oncology , 54 (1) pp. 79-85.

Pritchard, JK; Lewis, I; Whelan, JS; Hale, J; Pagonis, C; Durrant, LG; (2000) Immune response to the anti-idiotype cancer vaccine, 105AD7, following chemotherapy in osteosarcoma patients. In:

R

Ramon, D; Scott, I; Cox, ST; Pesoa, S; Vullo, C; Little, AM; Madrigal, JA; (2000) HLA-A*6817, identified in the Kolla Amerindians of North-West Argentina possesses a novel nucleotide substitution. Tissue Antigens , 55 (5) pp. 453-454.

Ramon, D; Scott, I; Cox, ST; Pesoa, S; Vullo, C; Little, AM; Madrigal, JA; (2000) HLA-A*6817, identified in the Kolla Amerindians of North-West Argentina possesses a novel nucleotide substitution. Tissue Antigens , 55 (5) pp. 453-454.

Raymond, EE; Fumoleau, P; Roche, H; Schellens, JHM; Dittrich, C; Punt, CJA; Droz, JP; ... Ravic, M; + view all (2000) Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clinical Cancer Research , 6 315-.

Rehman, S; Crow, J; Revell, PA; (2000) Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathology and Oncology Research , 6 (4) pp. 256-263.

Robinson, J; Marsh, SG; (2000) The IMGT/HLA sequence database. Rev Immunogenet , 2 (4) pp. 518-531.

Robinson, SP; Addada, J; Green, N; Wong, WL; Shaw, P; Chakraverty, R; Goldstone, AH; ... Linch, DC; + view all (2000) Response to short course ESHAP chemotherapy in relapsed and refractory lymphoma. BLOOD , 96 (11) 246B - 246B.

Rolfe, KJ; Crow, JC; Benjamin, E; Reid, WMN; MacLean, AB; Perrett, CW; (2000) Abnormalities in the G1/S cell cycle checkpoint in vulval cancer. BRIT J OBSTET GYNAEC , 107 (6) 817 - 817.

Roos, DE; Davis, SR; O'Brien, PC; Hoskin, PJ; (2000) Eligibility audits form the randomised neuropathic bone trial (TROG 96.05). Australasian Radiology , 44 pp. 303-307.

Roos, DE; O'Brien, PC; Smith, JG; Spry, NA; Hoskin, PJ; Burmeister, BH; Turner, SL; (2000) A role for radiotherapy in neuropathic bone pain: Preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05). International Journal of Radiation Oncology Biology Physics , 46 (4) pp. 975-981.

Rudd, RM; Gower, NH; James, LE; Gregory, W; Eisen, TQ; Lee, SM; et, A; (2000) A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). In: (Proceedings) 9th World Conference on Lung Cancer, Tokyo, Japan.. (pp. 21-). Lung Cancer

Rudd, RM; James, LE; Gower, NH; Gregory, W; Eisen, TQ; Harper, PG; Gilligan, D; ... Spiro, SG; + view all (2000) A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Lung Cancer , 29 (S1) 47-.

S

Sabin, CA; Yee, TT; Devereux, H; Griffioen, A; Loveday, C; Phillips, AN; Lee, CA; (2000) Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS , 14 (8) pp. 1001-1007.

Salomoni, P; Pandolfi, PP; (2000) Role of Daxx in B cell selection and apoptosis by CD40. BLOOD , 96 (11) 569A - +.

Salto-Tellez, M; Saunders, C; Kocjan, G; (2000) Diagnosis of multiple granular cell tumours by fine needle aspiration cytology. CYTOPATHOLOGY , 11 (3) 191 - 193.

Saunders, MI; (2000) The implications and opportunities of the CHART trial in the treatment of non-small cell lung cancer. British Journal of Cancer , 83 S5-.

Savage, K; Waller, HA; Khan, K; Dhillon, AP; Grimes, S; Michaeli, D; Pounder, RE; ... Caplin, ME; + view all (2000) Expression of CCK-B/gastrin receptor and endocytosis of anti-CCK-B/gastrin receptor antibody. Gut , 46 (S2) W96-.

Savage, K; Waller, HA; Khan, K; Dhillon, AP; Grimes, S; Michaeli, D; Pounder, RE; ... Caplin, ME; + view all (2000) Expression of CCK-B/gastrin receptor and endocytosis of anti-CCK-B/gastrin receptor antibody. Gastroenterology , 118 (4) 616-.

Sebire, NJ; Lader, CS; Roberts, L; Flanagan, AM; (2000) First trimester maternal serum Macrophage Colony-Stimulating Factor (M-CSF) is raised in pregnancies with subsequent severe pre-eclampsia. In: J PATHOL. (pp. 30A - 30A). JOHN WILEY & SONS LTD

Shah, EF; Woodside, J; Chatterjee, R; Stein, R; Saunders, C; (2000) The role of Zoladex in the prevention of ovarian damage during chemotherapy for primary breast cancer. BRIT J CANCER , 83 40 - 40.

Shah, N; Groom, N; Jackson, S; Sibtain, A; Hoskin, P; (2000) A pilot study to assess the feasibility of prior scalp cooling with palliative whole brain radiotherapy. British Journal of Radiology , 73 (869) pp. 514-516.

Shah, N; Hoskin, P; McMillan, A; Gibson, P; Lowe, J; Wong, WL; (2000) The impact of FDG positron emission tomography imaging on the management of lymphomas. British Journal of Radiology , 73 (869) pp. 482-487.

Shah, N; Hoskin, P; Sibtain, A; Baddeley, H; Taylor, J; Saunders, M; (2000) Blood oxygen level dependent (BOLD) MRI imaging: A non invasive assessment of hypoxia and perfusion in solid tumours. British Journal of Cancer , 83 15-.

Shah, N; Saunders, M; Dische, S; (2000) A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. British Journal of Cancer , 83 77-.

Shah, N; Sibtain, A; Saunders, MI; Townsend, E; Wong, WL; (2000) High FDG uptake in a schwanomma: A PET study. Journal Of Computer Assisted Tomography , 24 (1) pp. 55-56.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: (pp. p. 172).

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. British Journal of Cancer , 83 172-.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: (Proceedings) British Journal of Cancer. (pp. p. 71).

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KAAB; R, HJ; (2000) In vivo characteristics of a glycosylated fusion protein for prodrug activation. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 710-).

Shephard, EA; Janmohamed, A; Hernandez, D; McCombie, PR; Bootman, MA; Dolphin, CT; Smith, RL; ... Phillips, IR; + view all (2000) 13th International Symposium on Microsomes and Drug Oxidations. In: (Proceedings) Flavin-containing monooxygenases. : Stresa, Italy.

Short, S; (2000) UNSPECIFIED In: (Proceedings) Radiobiology 2000, Trivandrum, India.

Short, S; C, B; M, ; (2000) The treatment of malignant cerebral tumours. Hospital Medicine , 61 (11) pp. 772-777.

Short, SC; Traish, D; Dowe, A; Hines, F; Brada, M; (2000) UNSPECIFIED In: (Proceedings) 4th Congress of the European Association for Neuro-Oncology.

Sibtain, A; Bradshaw, A; Shah, N; Hoskin, PJ; (2000) Late complications of mantle radiotherapy for Hodgkin's lymphoma. British Journal of Cancer , 83 223-.

Sibtain, A; Hill, SA; Goodchild, KA; Shah, N; Saunders, MI; Hoskin, PJ; (2000) Modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. British Journal of Cancer , 83 15-.

Sibtain, A; Shah, N; Saunders, MI; Hoskin, PJ; (2000) Is there a relationship between pre-treatment haemoglobin and outcome in non-small cell lung cancer treated with radiotherapy? British Journal of Cancer , 83 58-.

Side, LE; Peniket, AJ; Levy, ER; Williamson, H; Humphray, SJ; Langabeer, SE; Walker, H; ... Wainscoat, JS; + view all (2000) Molecular characterization of the chromosome 9q deletion in AML. BLOOD , 96 (11) 542A - 542A.

Smith, PG; Thomas, HD; Barlow, HC; Griffin, RJ; Golding, BT; Calvert, AH; Newell, DR; (2000) In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research , 6 445-.

Somervaille, TCP; Linch, DC; Khwaja, A; (2000) Survival signalling in primary human erythroblasts occurs through PI3-kinase/Akt/GSK3 and not the classical MAP kinase pathway. BLOOD , 96 (11) 79A - 79A.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 35-.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. BRIT J CANCER , 83 16 - 16.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 (Suppl) 35-.

Spencer, DIR; Purdy, D; Minton, N; Whitelegg, NR; Rees, AR; Begent, RHJ; Chester, KA; (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. British Journal of Cancer , 83 (Suppl) 171-.

Spiro, SG; Gower, NH; Evans, MT; Facchini, FM; Rudd, RM; (2000) Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee. THORAX , 55 (6) pp. 463-465.

Steele, JP; Shamash, J; Evans, MT; Gower, NH; Tischkowitz, MD; Rudd, RM; (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Journal of Clinical Oncology , 18 (23) pp. 3912-3917.

Steele, JPC; Shamash, J; Gower, NH; Evans, MT; Tischkowitz, MD; Rudd, RM; (2000) Vinorelbine (Navelbine) given as a single agent for malignant pleural mesothelioma. Results from 65 patients at a single centre. Lung Cancer , 29 S18-.

Stephens, RJ; Gower, NH; Spir, S; S G, R; R M, OBOTBSC; (2000) The Big Lung Trials (BLT): a major randomised trial to determine the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Lung Cancer , 29 (Su 20-.

Stoeber, K; Williams, GH; (2000) A biochemical approach to cancer screening and diagnosis using antibodies against proteins that regulate DNA replication. In: Hospital Healthcare Europe 2000/2001. Campden Publishing Limited: London, UK.

Strauss, S; McTiernan, A; Driver, D; Hall-Craggs, M; Sandison, A; Cassoni, A; Kilby, A; ... Whelan, JS; + view all (2000) A single centre experience of an intensive induction therapy (VIDE) including stem cell collection for Ewing’s family of tumours (EFT). In:

Strauss, S; McTiernan, A; Whelan, JS; (2000) Spontaneous regression of pulmonary metastases in three patients with bone and soft tissue sarcomas. In:

Sud, R; Gale, RE; Harrison, CN; Machin, SJ; Linch, DC; (2000) Mutations in the TGF beta RII gene are unlikely to be responsible for the reduced sensitivity to TGF beta in megakaryocytes from patients with essential thrombocythaemia. BLOOD , 96 (11) 743A - 743A.

T

Tatton, L; Chopra, R; Khwaja, A; (2000) The selective Src kinase inhibitor PP1 also inhibits c-kit and Bcr-Abl tyrosine kinases and induces apoptosis in mast cell leukaemia, CML and AML cells. BLOOD , 96 (11) 81A - 81A.

Taylor, CPF; Mehta, AB; (2000) Infusional 5-fluorouracil in cutaneous leukaemia: A novel palliative therapy in haematological malignancy. Hematology , 5 (3) pp. 205-207.

Teixeira, R; Papatheodoridis, GV; Sabin, C; Davis, S; Dillon, AP; Dagher, L; Pastacaldi, S; ... Burroughs, AK; + view all (2000) Progression of liver fibrosis in patients with recurrent hepatitis C after orthotopic liver transplantation. HEPATOLOGY , 32 (4) 258A-258A.

Thomas, HD; Lind, MJ; Ford, J; Bleehen, N; Calvert, AH; Boddy, AV; (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. CANCER CHEMOTH PHARM , 45 (4) 284 - 290.

Tipping, AJ; Mathew, CG; (2000) Erythropoiesis: Current Clinical Practice: Advances in the Genetics and Biology of Fanconi Anaemia. Hematology , 5 (1) pp. 1-13.

Tipping, AJ; Zafirides, G; Mahon, FX; Goldman, JM; Melo, JV; (2000) Response of STI571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors. BLOOD , 96 (11) 98A - 98A.

Tkalcevic, J; Novelli, M; Phylactides, M; Iredale, JP; Segal, AW; Roes, J; (2000) Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity , 12 (2) pp. 201-210.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. British Journal of Cancer , 83 165-.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. British Journal of Cancer , 83 165-.

Tong, LFWT; Rolfe, KJ; Lewis, CE; Crow, JC; Reid, WMN; MacLean, AB; Perrett, CW; (2000) Effect of topical corticosteroids on angiogenic growth factors in vulval lichen sclerosus patients. J PATHOL , 192 23A - 23A.

Tripodis, N; Palmer, S; Phillips, S; Milne, S; Beck, S; Ragoussis, J; (2000) Construction of a high-resolution 2.5-Mb transcript map of the human 6p21.2-6p21.3 region immediately centromeric of the major histocompatibility complex. GENOME RES , 10 (4) 454 - 472.

Tsiompanou, E; Boxer, GM; Levine, T; Begent, RHJ; (2000) Immunohistochemical expression of vascular endothelial growth factor (VEGF) and vessel counting as prognostic indicators in node-negative colorectal cancer. BRIT J CANCER , 83 29 - 29.

Tsuzuki, S; Towatari, M; Saito, H; Enver, T; (2000) Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17) generated PML-RAR alpha oncoprotein. BLOOD CELLS MOLECULES AND DISEASES , 26 (5) p. 495.

V

Virchis, AE; Ganeshaguru, K; Hoffbrand, AV; Mehta, AB; Prentice, HG; Wickremasinghe, RG; (2000) A role for C-ABL tyrosine kinase in p53 upregulation and apoptosis in B-CLL cells exposed to chlorambucil. BLOOD , 96 (Abstr) 82a-.

Virchis, AE; Ganeshaguru, K; Hoffbrand, AV; Mehta, AB; Prentice, HG; Wickremasinghe, RG; (2000) A role for c-Abl tyrosine kinase in p53 upregulation and apoptosis in B-CLL cells exposed to chlorambucil. BLOOD , 96 (11) 82A - 82A.

van Zuylen, L; Eskens, FA; Bridgewater, J; Sparreboom, A; Sklenar, I; Planting, AS; Choi, L; ... Verweij, J; + view all (2000) The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study. Proceedings of the American Society for Clinical Oncology , 19 751-.

W

Waibel, R; Stichelberger, R; Alberto, R; Schubiger, PA; Chester, KA; Begent, RHJ; (2000) Site-directed labelling of single chain antibodies with 99(m)technetium and (188)rhenium. In: (pp. p. 15).

Wald, NJ; Hackshaw, AK; (2000) Advances in antenatal screening for Down Syndrome. In: UNSPECIFIED (563 - 580). BAILLIERE TINDALL

Wald, NJ; Hackshaw, AK; (2000) Principles of screening II: Multiple tests. In: Wald, NJ and Leck, I, (eds.) Antenatal and Neonatal Screening. (pp. 23-57). Oxford University Press

Wald, NJ; Hackshaw, AK; Cuckle, HS; (2000) Maternal serum alphafetoprotein screening for open neural tube defects: revised statistical parameters. BRIT J OBSTET GYNAEC , 107 (2) 296 - 298.

Wald, NJ; Hackshaw, AK; George, LM; (2000) Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J MED SCREEN , 7 (2) 74 - 77.

Wald, NJ; Hackshaw, AK; George, LM; (2000) Assay precision of serum alphafetoprotein in antenatal screening for neural tube defects and Down's syndrome (vol 7, pg 74, 2000). J MED SCREEN , 7 (3) 168 - 168.

Wald, NJ; Hackshaw, AK; Watt, H; (2000) Nuchal translucency and trisomy 18. PRENATAL DIAG , 20 (4) 353 - 354.

Watts, MJ; Somervaille, TCP; Ings, SJ; Ahmed, F; Khwaja, A; Yong, K; Linch, DC; (2000) Variable product purity and functional capacity after CD34+cell selection: A comparison of the CliniMACS and Isolex 300i clinical scale devices. BLOOD , 96 (11) 773A - 773A.

Westbury, C; Hines, F; Hawkes, E; Ashley, S; Brada, M; (2000) Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol , 54 (2) pp. 109-116.

Whelan, JS; (2000) Multidisciplinary care in a dedicated teenage cancer unit. In:

Whelan, JS; McTiernan, A; (2000) A Phase II study of docetaxel for the treatment of recurrent osteosarcoma and Ewing’s tumours. In:

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, A; (2000) Prolonged follow up of extremity osteosarcoma. Results from the European Osteosarcoma Intergroup. In:

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, A; European Osteosarcoma Intergrp, ; (2000) Long-term survival in localised extremity osteosarcoma: Mature follow-up from two randomised trials of the European Osteosarcoma Intergroup. In: BRIT J CANCER. (pp. 18 - 18). CHURCHILL LIVINGSTONE

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, AFTEOI; (2000) Localised extremity osteosarcoma: Mature survival data from two European Osteosarcoma Intergroup randomised clinical trials. In:

Whitely, W; Tariq, A; Peters, B; Kocjan, G; Miller, RF; (2000) Pyrexia of undetermined origin in the era of HAART. Sex Transm Infect , 76 (6) pp. 484-488.

Whitely, W; Tariq, A; Peters, B; Kocjan, G; Miller, RF; Kocjan, G; (2000) Pyrexia of undetermined origin in the era of HAART - (1) - Disseminated cryptococcosis - (2) - Immune reconstitution inflammatory syndrome with atypical mycobacteriosis causing lymphadenitis. SEX TRANSM INFECT , 76 (6) 484 - 488.

Wickremasinghe, RG; Ganeshaguru, K; Jones, DT; Glen, TA; Prentice, HG; Hoffbrand, AV; Mehta, AB; (2000) The AKT protein kinase mediates plasma-induced survival of B-CLL cells. British Journal of Haematology , 108 (Abstr) 72-.

Wickremasinghe, RG; Ganeshaguru, K; Jones, DT; Lewin, J; Prentice, HG; Hoffbrand, AV; Mehta, AB; (2000) Increases in cytoplasmic cytochrome c is not a rate-limiting step in the induction of apoptosis of B-CLL cells. British Journal of Haematology , 108 (Abstr) 72-.

Williamson, L; Cohen, H; Love, E; Jones, H; Todd, A; Soldan, K; (2000) The Serious Hazards of Transfusion (SHOT) initiative: the UK approach to haemovigilance. Vox sanguinis , 78 Sup pp. 291-295.

Wittke, B; Ensor, H; Chung, J; Birnbock, H; Lausecker, B; Ertel, SI; Mackie, IJ; (2000) Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. BRIT J CLIN PHARMACO , 49 (3) 231 - 239.

Wong, NK; Kanu, N; Thandrayen, N; Rademaker, GJ; Baldwin, CI; Renouf, DV; Hounsell, EF; (2000) Microassay analyses of protein glycosylation. Mol Biotechnol , 14 (2) pp. 147-155. 10.1385/MB:14:2:147.

Y

Yamano, H; Kitamura, K; Kominami, K; Lehmann, A; Katayama, S; Hunt, T; Toda, T; (2000) The spike of S phase cyclin Cig2 expression at the G1-S border in fission yeast requires both APC and SCF ubiquitin ligases. Mol. Cell , 6 (6) pp. 1377-1387.

Z

Ziegler, A; Ehlers, A; Forbes, S; Trowsdale, J; Uchanska-Ziegler, B; Volz, A; Younger, R; (2000) Polymorphic olfactory receptor genes and HLA loci constitute extended haplotypes. In: Kasahara, M, (ed.) MAJOR HISTOCOMPATIBILITY COMPLEX. (pp. 110 - 130). SPRINGER-VERLAG TOKYO

Ziegler, A; Ehlers, A; Forbes, S; Trowsdale, J; Volz, A; Younger, R; Beck, S; (2000) Polymorphisms in olfactory receptor genes: A cautionary note. HUM IMMUNOL , 61 (12) 1281 - 1284.

This list was generated on Sun Jun 17 02:30:07 2018 BST.